TY - JOUR
T1 - Drug Survival on First Biologic Therapy Among Late-Onset Rheumatoid Arthritis Patients Compared to Early-Onset Patients
T2 - A Population-Based Cohort Study
AU - Jeries, Helana
AU - Daood, Rula
AU - Hijazi, Basem
AU - Golan-Cohen, Avivit
AU - Green, Ilan
AU - Merzon, Eugene
AU - Naffaa, Mohammad E.
AU - Hassan, Fadi
N1 - Publisher Copyright:
© 2024 The Author(s). Musculoskeletal Care published by John Wiley & Sons Ltd.
PY - 2024/9
Y1 - 2024/9
N2 - Introduction: Rheumatoid arthritis (RA) patients can be divided according to the age of disease onset and classified as late-onset RA ≥ 60 years old or early-onset RA < 60 years old. Current treatment guidelines do not stipulate any preference regarding the biologic that should be used first in the late-onset group. This study aims to compare the drug survival times on first biological treatment between late and early-onset RA patients. Methods: This is a population based cohort study using the medical records of Leumit healthcare services. We included all eligible RA patients between 2000 and 2017. RA patients were divided into late- and early-onset RA groups and compared according to drug survival time on the first biological therapy. Results: The final cohort included 3814 RA patients, 2807 (73.6%) of whom had early-onset RA. Overall, biologic disease-modifying anti-rheumatic drugs (bDMARDs) were used more often among early-onset compared to late-onset patients (16.9% vs. 7.8%, p < 0.001). Among early-onset patients, etanercept was associated with the longest drug survival time on the first biologic, and adalimumab and infliximab were associated with the longest drug survival times among late-onset patients. No differences were observed in drug survival times between late and early-onset patients on the first bDMARD, except for abatacept and golimumab with longer drug survival time among early-onset patients. Conclusion: Late-onset RA patients were treated with biologics to a lesser extent than early-onset patients, but no differences were observed in drug survival times at the first bDMARD between the two groups.
AB - Introduction: Rheumatoid arthritis (RA) patients can be divided according to the age of disease onset and classified as late-onset RA ≥ 60 years old or early-onset RA < 60 years old. Current treatment guidelines do not stipulate any preference regarding the biologic that should be used first in the late-onset group. This study aims to compare the drug survival times on first biological treatment between late and early-onset RA patients. Methods: This is a population based cohort study using the medical records of Leumit healthcare services. We included all eligible RA patients between 2000 and 2017. RA patients were divided into late- and early-onset RA groups and compared according to drug survival time on the first biological therapy. Results: The final cohort included 3814 RA patients, 2807 (73.6%) of whom had early-onset RA. Overall, biologic disease-modifying anti-rheumatic drugs (bDMARDs) were used more often among early-onset compared to late-onset patients (16.9% vs. 7.8%, p < 0.001). Among early-onset patients, etanercept was associated with the longest drug survival time on the first biologic, and adalimumab and infliximab were associated with the longest drug survival times among late-onset patients. No differences were observed in drug survival times between late and early-onset patients on the first bDMARD, except for abatacept and golimumab with longer drug survival time among early-onset patients. Conclusion: Late-onset RA patients were treated with biologics to a lesser extent than early-onset patients, but no differences were observed in drug survival times at the first bDMARD between the two groups.
KW - biologic therapy
KW - early-onset rheumatoid arthritis
KW - late onset rheumatoid arthritis
KW - persistence
KW - rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=85201385360&partnerID=8YFLogxK
U2 - 10.1002/msc.1928
DO - 10.1002/msc.1928
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 39152548
AN - SCOPUS:85201385360
SN - 1478-2189
VL - 22
JO - Musculoskeletal Care
JF - Musculoskeletal Care
IS - 3
M1 - e1928
ER -